{"filing":{"accession_number":"0001104659-26-073496","cik":"0001393434","ticker":"OCUL","company_name":"OCULAR THERAPEUTIX, INC","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"tm2617802d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465926073496/tm2617802d1_8k.htm"},"events":[{"id":10774,"run_id":9453,"accession_number":"0001104659-26-073496","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Jason Robins was appointed as Chief Financial Officer, effective June 10, 2026. The appointment represents a material change in the company's financial leadership.","company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":7171,"accession_number":"0001104659-26-073496","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The principal disclosed action is the appointment of Jason Robins as Chief Financial Officer, effective June 10, 2026. While the section also discloses stockholder approval of an amendment to the 2021 Stock Incentive Plan and compensatory arrangements (salary, bonus, equity grants), the CFO appointment is the primary executive action. The appointment of a named executive officer to a C-suite position is material to investors assessing management continuity and financial leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:16:54.332295+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10775,"run_id":9453,"accession_number":"0001104659-26-073496","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"The 2026 Annual Meeting of Stockholders approved the election of Class III directors (Pravin U. Dugel, M.D. and Merilee Raines), advisory votes on named executive officer compensation and voting frequency, Amendment No. 5 to the 2021 Stock Incentive Plan increasing authorized shares by 10,000,000, and ratification of PricewaterhouseCoopers LLP as independent auditor.","company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":7172,"accession_number":"0001104659-26-073496","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the complete results of the 2026 Annual Meeting of Stockholders, including election of Class III directors (Pravin U. Dugel, M.D. and Merilee Raines), advisory votes on named executive officer compensation and voting frequency, approval of Amendment No. 5 to the 2021 Stock Incentive Plan increasing shares by 10,000,000, and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing directly states \"The following is a summary of the matters voted on at the 2026 Annual Meeting\" with detailed vote tallies for each proposal, which is the core disclosure required by Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:16:54.332295+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7171,"accession_number":"0001104659-26-073496","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The principal disclosed action is the appointment of Jason Robins as Chief Financial Officer, effective June 10, 2026. While the section also discloses stockholder approval of an amendment to the 2021 Stock Incentive Plan and compensatory arrangements (salary, bonus, equity grants), the CFO appointment is the primary executive action. The appointment of a named executive officer to a C-suite position is material to investors assessing management continuity and financial leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:16:54.332295+00:00","company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","filing_date":"2026-06-12"},{"id":7172,"accession_number":"0001104659-26-073496","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the complete results of the 2026 Annual Meeting of Stockholders, including election of Class III directors (Pravin U. Dugel, M.D. and Merilee Raines), advisory votes on named executive officer compensation and voting frequency, approval of Amendment No. 5 to the 2021 Stock Incentive Plan increasing shares by 10,000,000, and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing directly states \"The following is a summary of the matters voted on at the 2026 Annual Meeting\" with detailed vote tallies for each proposal, which is the core disclosure required by Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:16:54.332295+00:00","company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","filing_date":"2026-06-12"}]}